Navigation Links
CVBT Opens Florida and Arizona Sites for Its ACORD Phase II Heart Trial
Date:2/24/2009

LAS VEGAS, Feb. 24 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) announced today that two additional hospitals in the United States opened for patient enrollment for its ACORD Phase II clinical trial for the treatment of severe coronary heart disease. The sites are Florida Hospital/Cardiovascular Institute - Orlando Florida and Chandler Regional Medical Center and Mercy Gilbert Medical Center - Phoenix Arizona metropolitan area.

Mercy Hospital Fairfield (Ohio) and The Christ Hospital in Cincinnati, Ohio were first to open for enrollment in early September, and are working in collaboration to screen and treat patients in the trial. They treated their first patient in support of the trial in mid November 2008.

CVBT now has seven sites that are open for enrollment and intends to announce additional sites as they open for screening patents.

About CardioVascular BioTherapeutics

CVBT (OTCBB: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetics and in patients suffering from peripheral artery disease of the legs. An additional study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit www.cvbt.com.

    Media Contact:
    Allison Caplan,
    CardioVascular BioTherapeutics, Inc.
    (702) 839-7200, acaplan@cvbt.com

    Investor Contact:
    Yvonne Johnson
    CardioVascular BioTherapeutics, Inc.
    (702) 839-7220, investorrelations@cvbt.com


'/>"/>
SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial
2. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
3. EDICT Opens Public Comment Period for Clinical Trials Policy Recommendations
4. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
5. Medpace Opens Clinical Pharmacology Unit in Cincinnati, Ohio
6. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
7. PPD Opens Offices in Sydney, Australia; Copenhagen, Denmark; Lima, Peru; and Lisbon, Portugal
8. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
9. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
10. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , May 2, 2016 Kalorama Information ... (Electronic Medical Records) market in a recent white paper.  ... switches, Increased physician usage, a growing market are among ... noted in Kalorama,s report EMR 2016: The ... marks Kalorama,s seventh complete study of the EMR industry, ...
(Date:5/2/2016)...  Deerfield announced today it led the $44.5 ... Graybug Vision is an early stage pharmaceutical company ... for ocular diseases including wet age-related macular degeneration ... developed at Johns Hopkins University and has been ... Graybug Vision is developing ophthalmology products enabling ...
(Date:5/2/2016)... , May 2, 2016  Celsion Corporation (NASDAQ: ... today announced data from the first cohort of ... trial (the OVATION Study) combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  In the first three patients ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... ... Washington Wellness Center today announced its tenth anniversary of providing a complete approach to ... idea to provide a holistic approach to wellness has now become a growing trend ... Chiropractic Physician , the wellness center offers a complete range of services such ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nordic Naturals announces another ... metabolic health. This synergistic combination of omega-3 fatty acids and potent antioxidants contains ... of reduced glutathione and 200 mg of N-Acetylcysteine (NAC). , Each nutrient ...
(Date:5/4/2016)... ... 04, 2016 , ... The preeminent surgical aftercare facility Pearl Recovery Retreat was ... surgery. In March 2016, the 61-year-old model and reality TV star was diagnosed with ... the milk ducts, according to an interview with the Daily Mail Online . ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Warren L. ... Bladder infections, also called UTIs, have plagued people since the beginning of recorded ... women get bladder infections every year. It's not just a matter of inconvenience; bladder ...
(Date:5/4/2016)... ... ... Over 40 athletic trainer’s (ATs) and athletic training students (ATSs) from ... Harrisburg” advocacy day. The annual lobbying effort is a collaboration between the Pennsylvania ... for the day was to educate the elected legislators and the public about the ...
Breaking Medicine News(10 mins):